Menu
Search
|

Menu

Close
X

Pernix Therapeutics Holdings Inc PTX.OQ (NASDAQ Stock Exchange Global Market)

2.52 USD
+0.02 (+0.80%)
As of 2:29 AM IST
chart
Previous Close 2.50
Open 2.49
Volume 4,118
3m Avg Volume 21,914
Today’s High 2.52
Today’s Low 2.45
52 Week High 7.15
52 Week Low 2.00
Shares Outstanding (mil) 11.53
Market Capitalization (mil) 34.83
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY17
64
FY16
141
FY15
176
EPS (USD)
FY17
-5.100
FY16
-20.811
FY15
-27.419
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
0.26
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
-74.47
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

John Sedor
Chairman of the Board, Chief Executive Officer, Since 2016
Salary: $393,972.00
Bonus: $411,762.00
Angus Smith
Senior Vice President, Chief Business Officer and Principal Financial Officer, Since 2018
Salary: --
Bonus: --
Kenneth Pina
Senior Vice President, Chief Compliance Officer, General Counsel, Since 2017
Salary: --
Bonus: --
Glenn Whaley
Interim Vice President - Finance, Principal Accounting Officer, Corporate Controller, Since 2017
Salary: --
Bonus: --
John Leone
Lead Independent Director, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

10 N Park Pl Ste 201
MORRISTOWN   NJ   07960-7101

Phone: +1862.2608457

Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. Its products include Treximet, indicated for acute migraine; Zohydro ER with BeadTek, an extended-release opioid agonist indicated for the management of pain severe; Silenor for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla for major depressive disorder. It promotes selected non-core branded products, such as its cough and cold products, through co-promotion arrangements with third-party sales organizations, and distributes its generic products through its subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc.

SPONSORED STORIES